Therapy Areas: Autoimmune
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025
16 April 2025 -

Biopharmaceutical company TNF Pharmaceuticals Inc (Nasdaq: TNFA) announced on Wednesday that it presented its oral TNF-alpha inhibit...

Aditxt reports positive preclinical results from Mayo Clinic study supporting ADI-100 for autoimmune diseases
14 April 2025 - Aditxt Inc (NASDAQ: ADTX) reported on Monday that its wholly owned subsidiary Adimune Inc announced positive results from preclinical studies conducted by the Mayo Clinic, supporting t...
Sanofi's rilzabrutinib receives US orphan drug designation for two rare diseases
3 April 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday that the US Food and Drug Administration has granted orphan drug designation to rilzabrutin...
Organon acquires US rights to TOFIDENCE from Biogen
1 April 2025 - Healthcare company Organon (NYSE:OGN) announced on Tuesday that it has acquired the US regulatory and commercial rights to TOFIDENCE, a biosimilar to ACTEMRA, from biotechnology company...
Bio-Thera Solutions signs commercialisation and licence agreements with Dr. Reddy's Laboratories
28 March 2025 - Commercial-stage biopharmaceutical company Bio-Thera Solutions (SH:688177:SH) announced on Thursday that it has signed commercialisation and licence agreements with Dr. Reddy's La...
Hemogenyx's CAR-T therapy passes initial safety tests in Phase I trial
24 March 2025 - Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) announced on Monday that it has successfully treated the first patient in its Phase I clinical trial of HG-CT-1, a pro...